Study drug for focal epilepsy that isn’t controlled on current meds
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent after understanding the study risks and goals
- You’ve been diagnosed with focal epilepsy for at least 2 years
- You’ve tried at least two anti-seizure medicines (given at proper doses) but still don’t have sustained seizure freedom
- You’re on a stable dose of 1 to 3 allowed seizure medicines for at least 1 month and can keep it steady during the study
- You can accurately track your seizures using a seizure diary
- Your seizure type matches focal onset on EEG testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Hear when a new Focal Onset Seizures trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.